Royce & Associates LP Has $7.76 Million Stock Position in Zevra Therapeutics, Inc. $ZVRA

Royce & Associates LP raised its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 25.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 865,822 shares of the company’s stock after buying an additional 174,583 shares during the period. Royce & Associates LP owned 1.54% of Zevra Therapeutics worth $7,758,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Russell Investments Group Ltd. raised its stake in shares of Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after acquiring an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after acquiring an additional 8,552 shares during the last quarter. Creative Planning bought a new position in shares of Zevra Therapeutics during the second quarter valued at $92,000. Quarry LP bought a new position in Zevra Therapeutics during the third quarter worth $103,000. Finally, Qube Research & Technologies Ltd bought a new position in Zevra Therapeutics during the second quarter worth $99,000. Institutional investors own 35.03% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Guggenheim lifted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. BTIG Research assumed coverage on shares of Zevra Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $23.00 target price for the company. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, April 11th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.33.

Zevra Therapeutics Trading Up 4.1%

NASDAQ:ZVRA opened at $11.40 on Friday. The stock has a market capitalization of $673.97 million, a price-to-earnings ratio of 5.73 and a beta of 0.88. The firm has a fifty day simple moving average of $10.10 and a two-hundred day simple moving average of $9.29. Zevra Therapeutics, Inc. has a 12 month low of $7.16 and a 12 month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. Equities analysts predict that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.